Review
Accepted on 06 Feb 2025
CAR-T Cells in the Treatment of Multiple Myeloma: An Encouraging Cell Therapy
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1499590
Type at least 3 characters
7,152 articles
Articles
Original Research
Published on 06 Feb 2025
An anoikis-related signature predicts prognosis and immunotherapy response in gastrointestinal cancers
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1477913
- 482 views
Review
Published on 06 Feb 2025
Current status of cytokine-induced killer cells and combination regimens in breast cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1476644
- 482 views
Review
Published on 06 Feb 2025
KLF4: a multifunctional nexus connecting tumor progression and immune regulation
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1514780
- 469 views
Original Research
Published on 06 Feb 2025
Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1516332
- 448 views
Original Research
Published on 06 Feb 2025
Ddx21 mutant peptide is an effective neoantigen in prophylactic lung cancer vaccines and activates long-term anti-tumor immunity
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1500417
- 305 views
Original Research
Published on 06 Feb 2025
HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1449106
- 523 views
Systematic Review
Published on 06 Feb 2025
Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1515027
- 577 views
Hypothesis and Theory
Published on 06 Feb 2025
Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2024.1493978
- 755 views
Review
Published on 06 Feb 2025
Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1529847
- 1,034 views
Review
Published on 06 Feb 2025
Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1549276
- 475 views
Case Report
Accepted on 05 Feb 2025
Case Report: Efficacy of immune checkpoint inhibitors for high tumour mutational burden malignant phyllodes tumours of the breast as revealed by comprehensive genomic profiling
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1549452
Original Research
Accepted on 05 Feb 2025
Expression of SIRPα-Fc by Oncolytic Virus Enhances Antitumor Efficacy through Tumor Microenvironment Reprogramming
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1513555
- 106 views
Review
Accepted on 05 Feb 2025
Analysis of single-cell and spatial transcriptomics in TNBC cell-cell interactions
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1521388
Original Research
Accepted on 05 Feb 2025
The C/EBPβ antagonist peptide Lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1522699
- 125 views
Original Research
Accepted on 05 Feb 2025
Maplirpacept: A CD47 Decoy Receptor with Minimal Red Blood Cell Binding and Robust Anti-Tumor Efficacy
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2025.1518787
- 110 views